Table 4 |
|||
|
Summary of AEs and their relation to DSG treatment, outcome |
|||
|
Number of AE records |
Number of patients |
||
|
n |
n |
||
|
|
|||
|
Total AE |
329 |
21 |
|
|
Type of AE |
Infections and infestations |
59 |
18 |
|
Gastrointestinal disorders |
52 |
16 |
|
|
General disorders/administration site condition |
39 |
17 |
|
|
Intensity |
Mild |
218 |
21 |
|
Moderate |
90 |
18 |
|
|
Severe |
17 |
7 |
|
|
Outcome |
Resolved |
221 |
21 |
|
Additional therapy |
81 |
16 |
|
|
Hospitalization |
14 |
7 |
|
|
Premature termination |
8 |
5 |
|
|
Relationship to DSG |
No |
156 |
20 |
|
Unlikely |
42 |
15 |
|
|
Possibly |
86 |
18 |
|
|
Probably |
37 |
13 |
|
|
Definitely |
6 |
4 |
|
|
|
|||
|
AE, adverse event; DSG, deoxyspergualin. |
|||
|
Lorenz et al. Arthritis Research & Therapy 2011 13:R36 doi:10.1186/ar3268 |
|||
